Stay updated on Pembrolizumab in Hypermutation Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in Hypermutation Clinical Trial page.

Latest updates to the Pembrolizumab in Hypermutation Clinical Trial page
- Check6 days agoChange DetectedThe page footer now shows Revision: v3.3.3, and the previous Revision: v3.3.2 and the HHS Vulnerability Disclosure text have been removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check13 days agoNo Change Detected
- Check20 days agoNo Change Detected
- Check35 days agoChange DetectedThe changes update the Publications section wording to indicate that PubMed-listed publications are automatically populated from PubMed, and note the revision version. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check42 days agoChange DetectedA government funding/status notice at the top of the page was removed. This change does not affect the study content, eligibility criteria, or results of the trial. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check56 days agoChange DetectedThe updated screenshots show cosmetic UI adjustments with no changes to core trial information (status, enrollment, eligibility, outcomes). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check85 days agoChange DetectedAdds a current operating-status notice, a verified status entry with a date, and a new revision (v3.2.0); removes the old status and previous revision (v3.1.0).SummaryDifference3%

- Check92 days agoChange DetectedUpdated the page revision from v3.0.2 to v3.1.0, indicating a new software release or document update. No changes to core content, pricing, or stock are evident.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab in Hypermutation Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Hypermutation Clinical Trial page.